La letteratura scientifica nell’ambito della tecnologia DXA.
Aging is associated with decreases in muscle mass, strength, power (sarcopenia) and bone mineral density (BMD). The aims of this study were to investigate in elderly the role of sarcopenia on BMD loss by a path model, including adiposity, inflammation, and malnutrition associations…
View publication.
This study tested the hypothesis that nutritional supplementation with whey protein (22 g), essential amino acids (10.9 g, including 4 g leucine), and vitamin D [2.5 μg (100 IU)] concurrent with regular, controlled physical activity would increase fat-free mass, strength, physical function, and quality of life, and reduce the risk of malnutrition in sarcopenic elderly persons.
View publication.
The aim of this study was to evaluate the performance of Edmonton Frail Scale (EFS) on frailty assessment in association with multi-dimensional conditions assessed with specific screening tools and to explore the prevalence of frailty by gender.
View publication.
Sarcopenia, the decrease in muscle mass and function, may lead to various negative health outcomes in elderly. The association among sarcopenia with body adiposity and metabolic markers has rarely been studied in the elderly population, with controversial results. Aim of this study is evaluated the cross-sectional relationship between muscle mass loss and a composite variable of body adiposity and metabolic markers.
View publication.
For the growing numbers of obese elderly with diabetes, the glucagon-like peptide-1 (GLP-1) receptor analogue (liraglutide) appears a safe way to promote and maintain substantial weight loss. Given this background, the aim of this study was to assess the effect of the liraglutide treatment, at doses up to 3.0 mg per day, on the body composition, focusing on sarcopenia, in overweight and obese elderly with type 2 diabetes mellitus (T2DM).
View publication.
The aim of this study is to identify the prevalence, assess the metabolic profile, and key differences (versus healthy) in a cohort of subjects with sarcopenia (S) and in sarcopenic obesity (SO) hospitalized elderly.
View publication.
Whitepapers e report scientifici che ruotano attorno al mondo Lunar.
The management of osteoporosis underwent a paradigm shift in 1995 with the approval of the first bisphosphonate, risedronate. Since then, several other bisphosphonates have been approved, including alendronate, ibandronate, and zoledronate, as well as the first biologic treatment for osteoporosis, denosumab. These drugs reduce fracture risk by decreasing bone resorption. Their use is attributed to a significant reduction in the incidence and mortality of hip fractures since 1995.
DXA stands for Dual-Energy X-ray Absorptiometry. It is a measurement method that uses the differences in the absorption of high energy and low energy X-ray photons by different elements in a body to quantify the amount of bone and soft tissue in the body. For example, certain elements in bone minerals (e.g. calcium) will absorb more low-energy X-rays than the elements in soft tissue, enabling a precise and accurate estimate of bone mineral density (BMD). By using relevant algorithms, we can also use the same measured data to determine body composition due to the different density and composition of fat and lean tissue. Based on DXA technology, the GE Healthcare Lunar bone densitometry product portfolio (iDXA, Prodigy, and Aria) empowers physicians and clinicians to diagnose osteoporosis and fracture risk. iDXA and Prodigy may also perform body composition analysis (fat and lean tissue mass). After a DXA scan, the measured values are compared to a reference population at the sole discretion of the physician to achieve desired clinical results.
The World Health Organization defines osteoporosis as a silent disease characterized by low bone mass (bone density) and microarchitectural deterioration of bone tissue leading to increased bone fragility and elevated risk of fracture. Worldwide, osteoporosis affects an estimated 200 million women and causes nearly nine million fractures annually. Globally, one in three women and one in five men over the age of 50 will experience a fracture due to osteoporosis with a subsequent decrease in quality of life and an excess mortality rate for hip fractures >20% in the first year- By 2050, the worldwide incidence of hip fracture in women is projected to increase by 240% and in men by 310%.
The classical definition of obesity is the accumulation of excess adipose tissue (fat) to the point where health is negatively impacted. Because it has historically been difficult to measure the amount of fat in the body, physicians have relied on indices such as body mass index (BMI). Measurement of BMI is attractive to clinicians because it is cost effective; however, BMI is not always a reliable indicator of metabolic disease. In fact, studies have shown that 30% of individuals with obese BMI are metabolically healthy, and 20% of subjects with healthy BMI have metabolic disease2. Better identification of metabolic risk requires that we look beyond BMI and consider metabolic phenotyping based on body composition measures.
